Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Teva Pharmaceutical Industries Ltd
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 39.19 · gapped below the open, then crossed back over prior close. High/low 39.29 at 12:45 pm ET, 38.39 at 10:45 am ET.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of TEVA revenue | Skew |
|---|---|---|---|
| ALVOAlvotech | 40.00% | 1.80% | 22× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We currently depend on Teva Pharmaceuticals Industries Ltd, as our single-source supplier of mitomycin API for Jelmyto, Zusduri, UGN-103 and UGN-104.”
FILING10-K0001437749-26-006234cik 0001668243disclosed by URGN
“In October 2021, we entered into an asset purchase agreement, or the Teva Agreement, with Teva Pharmaceutical Industries, Ltd. and its affiliate Cephalon, Inc., or, together Teva, pursuant to which we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds, and we assumed all post-acquisition liabilities related thereto.”
FILING10-K0001999480-26-000002cik 0001999480disclosed by ANRO
“In December 2024, the Company acquired GALZIN® (zinc acetate) from Teva Pharmaceuticals USA, Inc and assumed the commercialization of the product in the U.S. during March of 2025.”
FILING10-K0001437749-26-009059cik 0001710340disclosed by ETON
“Pursuant to the terms of a confidential settlement and license agreement entered into in August 2023 with Teva, we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license under the remaining patent covering VIVITROL to market and sell a generic version of VIVITROL in the U.S. beginning on the First Entry Date, or earlier under certain circumstances.”
FILING10-K0001193125-26-068925cik 0001520262disclosed by ALKS
“In connection with the Teva LDA, we also entered into a product supply agreement with Teva in August 2020 (the "Teva PSA") for the manufacture and supply of each product in the Teva Territory covered by the Teva LDA. Pursuant to the Teva PSA, Teva will remit approximately 40% of its in-market sales to us in the form of sales-based royalties.”
$311M relationship22× more of ALVO’s book than TEVA’s
basisALVO fy2025 · closed 2025-12 $779MTEVA fy2025 · closed 2025-12 $17.3B
FILING20-F0001898416-26-000004cik 0001898416disclosed by ALVO
“CEL-SCI has already licensed future sales of Multikine, if approved, to three companies: Teva Pharmaceutical Industries Ltd. in Israel, Turkey, Serbia and Croatia; Orient Europharma in Taiwan, Singapore, Hong Kong, Malaysia, South Korea, the Philippines, Australia and New Zealand; and Byron BioPharma, LLC in South Africa.”
FILING10-K0001654954-25-014303cik 0000725363disclosed by CVM
“Phase 3 programs for duvakitug (anti-TL1A) in ulcerative colitis and Crohn's disease were initiated by Sanofi and Teva in October 2025;”
FILING10-K0001193125-26-034532cik 0000818686
“The FDA has approved Abbreviated New Drug Applications (ANDA) for generic versions of HETLIOZ ® for Teva Pharmaceuticals USA, Inc. (Teva), Apotex Inc. (Apotex) and MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN).”
FILING10-K0001628280-26-007460cik 0001347178disclosed by VNDA
Watchlist prices, news filtered to it, and its next report on your desk.
Teva Pharmaceutical Industries Ltd has 3 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Teva Pharmaceutical Industries Ltd’s own annual report or the counterparty’s, and carries the sentence that discloses it.
TEVA (Teva Pharmaceutical Industries Ltd) has 3 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ETON −4.73%, in healthcare.